急性肺栓塞全身溶栓证据的稳健性与脆弱性
该研究系统评价9项RCT(1682例)比较静脉阿替普酶或替奈普酶与肝素,发现全因死亡下降不显著且证据脆弱,高危PE的死亡获益极脆弱(RFI=0),而大出血风险稳健增加。
要点
- 全身溶栓降低全因死亡不显著,证据稳健性中等(RFI=8)。
- 高危PE死亡获益极脆弱(RFI=0),中危PE亦脆弱(RFI=4)。
- 大出血风险稳健增加(FI=30,NNH=17),主要由替奈普酶驱动。
核心结论
- 全身溶栓的死亡获益证据脆弱,而大出血风险证据稳健,提示现有指南存在局限。
研究设计与样本
- 系统评价9项RCT,共纳入1682例患者,比较静脉阿替普酶或替奈普酶与肝素。
- 主要终点为全因死亡,次要终点包括复发性PE、中危患者临床恶化和大出血。
- 计算脆弱指数(FI)或反向FI(RFI)及脆弱商(FQ)或反向FQ(RFQ)评估结局稳定性。
主要发现
- 全因死亡:溶栓组1.7% vs 对照组3.8%,RR 0.73(95%CI 0.39-1.38;p=0.33),RFI=8,RFQ=0.004,NNT=91,RRR=27%,ARR=2.1%。
- 复发性PE:RR 0.42(95%CI 0.18-0.97),FI=5,RFQ=0.002。
- 中危患者临床恶化:RR 0.31(95%CI 0.15-0.65),FI=8,RFQ=0.006,NNT=29,RRR=71%,ARR=3.5%。
- 大出血:FI=30,RFQ=0.001,NNH=17;替奈普酶亚组FI=9,RFQ=0.007,NNH=11;阿替普酶无显著增加(RFI=3)。
- 死亡获益在高危PE中极脆弱(RFI=0),在中危患者中脆弱(RFI=4)。
临床怎么用
- 临床决策需权衡全身溶栓的脆弱死亡获益与稳健增加的大出血风险。
- 高危和中危PE的个体化治疗应结合证据脆弱性,不应仅依据指南推荐。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
J Thromb Thrombolysis. 2026 Oct;59(7):1996-2006. doi: 10.1007/s11239-026-03344-x. Epub 2026 Jun 18. ABSTRACT Systemic thrombolysis is recommended for high-risk PE and select intermediate-risk patients. We assessed the robustness of RCT evidence comparing systemic thrombolytic therapy with standard anticoagulation. We systematically reviewed RCTs of intravenously administered alteplase or tenecteplase versus heparin. The primary endpoint was all-cause mortality; secondary endpoints included recurrent PE, clinical deterioration in intermediate-risk patients, and major bleeding. Fragility index (FI) or reverse FI (RFI) and fragility quotient (FQ) or reverse FQ (RFQ) were calculated to assess outcome stability. Absolute and relative risk reductions, number needed to treat (NNT), and number needed to harm (NNH) were also derived. Nine RCTs enrolling 1,682 patients met inclusion criteria. Overall, systemic thrombolysis was associated with a nonsignificant reduction in mortality (1.7% vs. 3.8%; RR 0.73; 95% CI 0.39-1.38; p = 0.33) with moderate robustness (RFI = 8; RFQ = 0.004; NNT 91; RRR 27%; ARR 2.1%). Mortality was highly fragile in high-risk PE (RFI = 0) and fragile in intermediate-risk patients (RFI = 4). Systemic thrombolysis moderately reduced recurrent PE (RR 0.42; 95% CI 0.18-0.97; FI = 5; RFQ = 0.002) and prevented clinical deterioration in intermediate-risk patients (RR 0.31; 95% CI 0.15-0.65; FI = 8; RFQ = 0.006; NNT 29; RRR 71%; ARR 3.5%). Major bleeding was robustly increased (FI = 30; RFQ = 0.001; NNH 17), mainly driven by tenecteplase (FI = 9; RFQ = 0.007; NNH 11), whereas alteplase showed no significant increase (RFI = 3). Mortality benefit of systemic thrombolysis is fragile, while major bleeding risk is robust, underscoring the limitations of current guidelines and the need for adequately powered RCTs to inform individualized treatment in high- and intermediate-risk PE. PMID: 42315722 | DOI: 10.1007/s11239-026-03344-x
引用
- PubMed 高证据 · 肺栓塞:Robustness and fragility of evidence supporting systemic thrombolysis in acute pulmonary embolism
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。